Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  SHANGHAI STOCK EXCHANGE  >  Tasly Pharmaceutical Group Co Ltd    600535   CNE000001C81

TASLY PHARMACEUTICAL GROUP CO LTD

(600535)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Tasly Pharmaceutical : The Announcement of FDAⅢ Progress of Dantonic Pill by Tasly Phar. Group Co.,Ltd (2016-03-29)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/30/2016 | 12:26pm EDT

According to relevant regulations of No.7 Guidance for Information Disclosure of Listed Companies for pharmaceutical manufacture sector, the company, who will get the summary report about a clinic trial, should disclose relevant information about the medicine, project investment, development progress and marketing status in time.

Tasly Phar. Group Co.,Ltd hereby declares that all clinical development phase of Dantonic (T89) for us FDA clearance have been completed. The site closure visit procedure for the pivotal phase Ⅲ trial is in progress.

The final trial result will be released when the summary report of the clinical trial is available after database locking, data analysis and unblind steps.

Tianjin Tasly Pharmaceutical Co. Ltd. issued this content on 29 March 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 30 March 2016 16:25:18 UTC

Original Document: http://www.tasly.com/show.aspx?id=11123&cid=22

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TASLY PHARMACEUTICAL GROUP
2018TASLY PHARMACEUTICAL : and Mesoblast Initiate Development and Regulatory Activit..
AQ
2018MESOBLAST : Tasly and MSB Initiate Activities for MPC-150-IM in China
AQ
2018MESOBLAST : Tasly Receives Approvals For Transaction With MSB
AQ
2018MESOBLAST : Tasly Pharmaceutical Group Receives All Necessary Approvals for Tran..
AQ
2018TRANSGENE : Tasly Biopharmaceuticals gains control of JV ahead of possible IPO
AQ
2018HONG KONG EXCHANGES AND CLEARING : China's Tasly to list biotech arm in $1 billi..
RE
2017TASLY PHARMACEUTICAL : VP Receives Attendees of High-level Workshop
PU
2017TASLY PHARMACEUTICAL : Leaders from BRICS Ministry of Health Visited Tasly
PU
2017TASLY PHARMACEUTICAL : Minister-counselor of Embassy of South America in Beijing..
PU
2016TASLY PHARMACEUTICAL : won Top 20 of Most Competitive Pharmaceutical Listed Comp..
PU
More news
Financials (CNY)
Sales 2019 20 667 M
EBIT 2019 2 590 M
Net income 2019 1 838 M
Debt 2019 6 687 M
Yield 2019 1,77%
P/E ratio 2019 18,74
P/E ratio 2020 16,23
EV / Sales 2019 1,98x
EV / Sales 2020 1,76x
Capitalization 34 302 M
Chart TASLY PHARMACEUTICAL GROUP CO LTD
Duration : Period :
Tasly Pharmaceutical Group Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TASLY PHARMACEUTICAL GROUP
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 28,0  CNY
Spread / Average Target 24%
EPS Revisions
Managers
NameTitle
Yong Hong Zhu General Manager & Director
Kai Jing Yan Chairman
Zheng Liang Ye Chairman-Supervisory Board
Xi Jun Yan Honorary Chairman
Xiao Meng Jiang Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
TASLY PHARMACEUTICAL GROUP CO LTD17.86%5 103
JOHNSON & JOHNSON6.80%372 522
ROCHE HOLDING LTD.10.11%227 132
PFIZER-9.69%218 852
NOVARTIS4.88%195 750
MERCK AND COMPANY-2.37%192 697